Clinical Trials
2 trialsNCT06282874 2026-04-09
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Phase 4 Active not recruiting
NCT06893354 2025-03-25
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
The First Affiliated Hospital of Guangzhou Medical University
Phase 4 Not yet recruiting